Patents Examined by Stephanie W. Zitomer
  • Patent number: 6514693
    Abstract: A method for detecting or quantitating multiple copies of a repeat sequence in a nucleic acid molecule involving treating the nucleic acid molecule with a probe which is a nucleic acid analogue which is capable of hybridizing to the repeat sequence in the nucleic acid molecule and which is labelled with a detectable substance. The nucleic acid molecule is treated with the probe under conditions permitting the probe to hybridize to the repeat sequences in the nucleic acid molecule. Probe hybridized to complementary repeat sequences is identified in the nucleic acid molecule by directly or indirectly detecting the detectable substance. The method is preferably used for quantitating multiple copies of a repeat sequence in a nucleic acid molecule, preferably a telomere or centromere repeat sequence. Novel probes for use in the method of the invention and kits are described.
    Type: Grant
    Filed: October 11, 1996
    Date of Patent: February 4, 2003
    Assignee: Tetramerics Biotechnology, Inc.
    Inventor: Peter Lansdorp
  • Patent number: 6503721
    Abstract: The present invention provides methods for high-throughput screening for bioactive compounds, in particular those that bind to RNA sequences involved in the pathogenesis of disease or in regulation of a physiological function. The methods involve measuring the conformation of an RNA target in the presence and absence of test ligands, and identifying as a ligand any test ligand that causes a measurable change in target RNA conformation.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: January 7, 2003
    Assignee: Anadys Pharmaceuticals, Inc.
    Inventors: Jaime E. Arenas, James W. Lillie, Andrew Pakula
  • Patent number: 6482594
    Abstract: Methods to obtain nucleic acid ligands that photocrosslink to target molecules associated with a disease state are provided. The methods presented are variations on the photoSELEX methods for obtaining nucleic acid ligands. In one method, a candidate mixture of photocrosslinkable nucleic acids is contacted with a biological substance obtained from a source associated with a disease state suspected of containing a target molecule to form nucleic acid-target molecule complexes, the complexes are irradiated to form crosslinked complexes, the photocrosslinked complexes are partitioned from the remainder of the candidate mixture; and the nucleic acid ligands that photocrosslink to molecule are retained. These nucleic acids are then contacted with a second biological substance of the same type as the first, but obtained from a source not associated with a disease state. This removes nucleic acids with affinity to molecules that are not associated with the disease state.
    Type: Grant
    Filed: June 14, 2001
    Date of Patent: November 19, 2002
    Assignee: SomaLogic, Inc.
    Inventors: Larry Gold, Michael Willis, Tad Koch, Steven Ringquist, Kirk Jensen, Brent Atkinson
  • Patent number: 6479235
    Abstract: Methods and materials are disclosed for use in simultaneously amplifying at least thirteen loci of genomic DNA in a single multiplex reaction, as are methods and materials for use in the analysis of the products of such reactions. Included in the present invention are materials and methods for the simultaneous amplification of at least thirteen short tandem repeat loci, including specific materials and methods for the analysis of thirteen such loci specifically selected by the United States Federal Bureau of Investigation as core loci for use in the Combined DNA Index System (CODIS) database.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: November 12, 2002
    Assignee: Promega Corporation
    Inventors: James W. Schumm, Cynthia J. Sprecher
  • Patent number: 6465629
    Abstract: The present invention relates to the relation of the BRG1 gene (also called SNF2&agr;) to human cancers and its use in the diagnosis and prognosis of human cancer. The invention also relates to the therapy of human cancers which have a mutation in the BRG1 gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.
    Type: Grant
    Filed: March 23, 2000
    Date of Patent: October 15, 2002
    Assignee: Myriad Genetics, Inc.
    Inventors: Alexander K. C. Wong, Sean V. Tavtigian, David H. F. Teng
  • Patent number: 6458545
    Abstract: A biochip which is extremely safe and enables reduction of cost of testing and which comprises in sequence from opening of a blood collecting tube thereof: a collection block for retaining collected blood; a preprocessing block for deriving a target from the collected blood; and a substrate on which probes are deposited in arrays and the opening is closed airtight with a rubber plug.
    Type: Grant
    Filed: February 15, 2001
    Date of Patent: October 1, 2002
    Assignee: Yokogawa Electric Corporation
    Inventor: Takeo Tanaami
  • Patent number: 6451996
    Abstract: The conditions under which oligonucleotides hybridize only with entirely homologous sequences are recognized. The sequence of a given DNA fragment is read by the hybridization and assembly of positively hybridizing probes through overlapping portions. By simultaneous hybridization of DNA molecules applied as dots and bound onto a filter, representing single-stranded phage vector with the cloned insert, with about 50,000 to 100,000 groups of probes, the main type of which is (A,T,C,G)(A,T,C,G)N8(A,T,C,G), information for computer determination of a sequence of DNA having the complexity of a mammalian genome are obtained in one step. To obtain a maximally completed sequence, three libraries are cloned into the phage vector, M13, bacteriophage are used: with the 0.5 kb and 7 kbp insert consisting of two sequences, with the average distance in genomic DNA of 100 kbp. For a million bp of genomic DNA, 25,000 subclones of the 0.5 kbp are required as well as 700 subclones 7 kb long and 170 jumping subclones.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: September 17, 2002
    Assignee: Callida Genomics, Inc.
    Inventors: Radoje T. Drmanac, Radomir B. Crkvenjakov
  • Patent number: 6444423
    Abstract: The present invention provides for the selective covalent modification of nucleic acids with redox active moieties such as transition metal complexes. Electron donor and electron acceptor moieties are covalently bound to the ribose-phosphate backbone of a nucleic acid at predetermined positions. The resulting complexes represent a series of new derivatives that are bimolecular templates capable of transferring electrons over very large distances at extremely fast rates. These complexes possess unique structural features which enable the use of an entirely new class of bioconductors and photoactive probes.
    Type: Grant
    Filed: November 13, 1998
    Date of Patent: September 3, 2002
    Assignee: Molecular Dynamics, Inc.
    Inventors: Thomas J. Meade, Thomas W. Welch
  • Patent number: 6440672
    Abstract: The invention relates to methods for identifying inhibitors of mucin production, methods for inhibiting mucin production and methods for treating airway diseases, such as cystic fibrosis, chronic bronchitis, bronchial pneumonia and asthma. Compositions are provided for use in the method comprising reporter gene constructs which are inducible by mucomones.
    Type: Grant
    Filed: April 20, 2000
    Date of Patent: August 27, 2002
    Assignee: The Regents of the University of California
    Inventors: Carol Basbaum, Marianne Gallup, Daizong Li, Assefa Gebremichael, Erin Gensch
  • Patent number: 6432644
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: November 22, 1999
    Date of Patent: August 13, 2002
    Assignee: University of Utah Research Foundation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Igor Splawski
  • Patent number: 6429011
    Abstract: The gene for autosomal recessive neurodegenerative disorder Spinal Muscular Atrophy has been mapped to a region of chromosome 5. The gene encodes a protein having homology with apoptosis inhibitor proteins of viruses so that the encoded protein has been labelled as a neuronal apoptosis inhibitor protein (NAIP). A deletion in the (NAIP) domain was identified in persons with Type I, II and III Spinal Muscular Atrophy (SMA) and not in the normal non-SMA population.
    Type: Grant
    Filed: January 28, 2000
    Date of Patent: August 6, 2002
    Assignees: University of Ottawa, Research Development Corporation of Japan
    Inventors: Alex E. MacKenzie, Robert G. Korneluk, Natalie Roy, Mani S. Mahadevan, Michael McLean, Joh-E Ikeda
  • Patent number: 6423492
    Abstract: A method is disclosed for detecting single-stranded target nucleic acid (2) which comprises the steps of forming a hybrid between said target nucleic acid and a nucleic acid probe (4), said nucleic acid probe labelled with an enzyme reagent (6) which hydrolyses single-stranded nucleic acid but is substantially without effect on double-stranded nucleic acid, said hybrid formed under conditions of pH which are outside the activity range of said enzyme reagent, adjusting said pH to a value within the activity range of said enzyme reagent allowing said enzyme reagent substantially to hydrolyse any single-stranded nucleic acid present, and detecting said hybrid.
    Type: Grant
    Filed: October 14, 1999
    Date of Patent: July 23, 2002
    Assignee: Zetatronics Limited
    Inventor: Stuart Harbron
  • Patent number: 6410229
    Abstract: This invention provides methods of monitoring the expression levels of a multiplicity of genes. The methods involve hybridizing a nucleic acid sample to a high density array of oligonucleotide probes where the high density array contains oligonucleotide probes complementary to subsequences of target nucleic acids in the nucleic acid sample.
    Type: Grant
    Filed: December 14, 1998
    Date of Patent: June 25, 2002
    Assignee: Affymetrix, Inc.
    Inventors: David J. Lockhart, Eugene L. Brown, Gordon G. Wong, Mark S. Chee, Thomas R. Gingeras
  • Patent number: 6406855
    Abstract: Methods are provided for the evolution of proteins of industrial and pharmaceutical interest, including methods for effecting recombination and selection. Compositions produced by these methods are also disclosed.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: June 18, 2002
    Assignee: Maxygen, Inc.
    Inventors: Phillip A. Patten, Willem P. C. Stemmer
  • Patent number: 6403309
    Abstract: The present invention is directed to methods and compositions for use in screening nucleic acid populations for nucleic acid polymorphisms. The methods, referred to generally as ValiGeneSM Mutation Screening, Peptide-Linked (VGMS-PL) methods, are specifically designed for high-throughput genotype mapping and gene expression analysis of animal and plant nucleic acids without requiring a PCR amplification step. In particular, the methods of the invention utilize oligonucleotide probes labeled with distinguishable and identifiable peptide tags, that are captured on addressable antibody arrays.
    Type: Grant
    Filed: March 19, 1999
    Date of Patent: June 11, 2002
    Assignee: ValiGen (US), Inc.
    Inventors: Francois J.-M. Iris, Jean-Louis Pourny
  • Patent number: 6399302
    Abstract: The present invention relates to oligonucleotide-based biosensors and a general method for their production and use. Specifically, the invention describes a novel signal-generating ligand complex comprising the combination of two or more aptamers linked together by a polymeric linker and further comprising a signaling system that provides a detectable signal upon binding of the signal-generating ligand complex to its target analyte.
    Type: Grant
    Filed: April 19, 2000
    Date of Patent: June 4, 2002
    Assignee: University of Virginia Patent Foundation
    Inventors: Deborah A. Lannigan, Ian G. Macara
  • Patent number: 6399301
    Abstract: The invention provides a human phospholipase A2 protein PHPLA2 and polynucleotides which identify and encode PHPLA2. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of PHPLA2.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: June 4, 2002
    Assignee: Incyte Genomics, Inc.
    Inventors: Phillip R. Hawkins, Olga Bandman, Karl J. Guegler, Purvi Shah, Neil C. Gorley
  • Patent number: 6399308
    Abstract: The present invention relates to an isolated protein or polypeptide corresponding to a protein or polypeptide of a Rupestris stem pitting associated virus. The encoding DNA molecule, either alone in isolated form, in an expression system, a host cell, or a transgenic grape plant, is also disclosed. Other aspects of the present invention relate to a method of imparting Rupestris stem pitting associated virus resistance to grape plants by transforming them with the DNA molecule of the present invention, and a method of detecting the presence of a Rupestris stem pitting associated virus, such as RSPaV-1, in a sample.
    Type: Grant
    Filed: November 7, 2000
    Date of Patent: June 4, 2002
    Assignee: ProfiGen Inc.
    Inventors: Dennis Gonsalves, Baozhong Meng
  • Patent number: 6399299
    Abstract: The present invention concerns an array-based analytical system and method having an enhanced sensitivity which allows for simple and rapid analysis of relative unmodified samples which comprises an analytical system of the type having a plurality of different first members of a specific binding pair affixed in an array thereupon, a mixture including at least one second member of a specific binding pair capable of binding to one of the first members so as to form a specific binding pair which is affixed to the support member, and a reporter system that produces a detectable signal indicative of the presence of the specific binding pair on the support member and wherein the reporter system includes an amplified reporter system that is independent of layering.
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: June 4, 2002
    Assignee: PerkinElmer Life Sciences, Inc.
    Inventors: Mark Norman Bobrow, Karl Edwin Adler
  • Patent number: 6399762
    Abstract: The present invention relates of the mammalian HKNG1 gene, a gene associated with bipolar affective disorder (BAD) in humans. The invention relates, in particular, to methods for the diagnostic evaluation, genetic testing and prognosis of HKNG1 neuropsychiatric disorders including schizophrenia, attention deficit disorder, a schizoaffective disorder, a bipolar affective disorder or a unipolar affective disorder.
    Type: Grant
    Filed: September 7, 2000
    Date of Patent: June 4, 2002
    Assignees: The Regents of the University of California, Millennium Pharmaceuticals, Inc.
    Inventors: Hong Chen, Nelson B. Freimer